title: The sad story of Vioxx, and what we should learn from it.
authors.affiliation: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: Juhana
authors.initials: J
authors.lastname: Karha
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000139:chemically induced; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007783:Lactones; D013450:Sulfones; C116926:rofecoxib